Panaxia and Neuraxpharm To Exclusively Distribute Medical Cannabis Extracts For Inhalation In European Market

June 21 2021 | Benzinga

by Jelena Martinovic

Panaxia and Neuraxpharm To Exclusively Distribute Medical Cannabis Extracts For Inhalation In European Market

Israel’s largest manufacturer and home-delivery distributor of medical cannabis products, Panaxia Labs Israel Ltd., and its German partner Neuraxpharm received the green light to market and distribute medical cannabis extracts for inhalation, making them the first to exclusively sell this type of product in Europe.

The marketing permit issued by German authorities allows Panaxia’s strategic partner, Neuraxpharm, to import products and then distribute them to pharmacies and market to physicians.

Dr. Dadi Segal, founder and CEO of Panaxia Israel, said Monday that they are thrilled to be the “first and exclusive” company in Europe to obtain the marketing permit.

“This is an unprecedented commercial and regulatory achievement and significant news for patients in Germany, who will now be able to consume, for the first time, a clean product,” Segal said.

Read more on Benzina

Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on twitter
Twitter